OmniAb (NASDAQ:OABI – Get Free Report) and Caris Life Sciences (NASDAQ:CAI – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.
Institutional & Insider Ownership
72.1% of OmniAb shares are owned by institutional investors. 9.8% of OmniAb shares are owned by company insiders. Comparatively, 50.0% of Caris Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares OmniAb and Caris Life Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OmniAb | $18.67 million | 39.84 | -$64.78 million | ($0.34) | -15.00 |
| Caris Life Sciences | $812.03 million | 8.65 | -$68.09 million | $0.33 | 74.21 |
OmniAb has higher earnings, but lower revenue than Caris Life Sciences. OmniAb is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings for OmniAb and Caris Life Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OmniAb | 1 | 0 | 3 | 0 | 2.50 |
| Caris Life Sciences | 1 | 5 | 8 | 0 | 2.50 |
OmniAb presently has a consensus target price of $11.50, suggesting a potential upside of 125.49%. Caris Life Sciences has a consensus target price of $31.18, suggesting a potential upside of 27.32%. Given OmniAb’s higher probable upside, research analysts plainly believe OmniAb is more favorable than Caris Life Sciences.
Risk & Volatility
OmniAb has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Caris Life Sciences has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
Profitability
This table compares OmniAb and Caris Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OmniAb | -108.11% | -16.74% | -14.79% |
| Caris Life Sciences | 9.16% | 16.00% | 8.05% |
Summary
Caris Life Sciences beats OmniAb on 9 of the 13 factors compared between the two stocks.
About OmniAb
OmniAb, Inc. is a biotechnology company that develops antibody discovery technologies for use in creating therapeutic medicines. It works with pharmaceutical and biotechnology companies to identify and advance antibody candidates for potential drug development. Its platform includes genetically engineered animals that can produce antibodies with human characteristics, along with related discovery and screening technologies. These tools are designed to help partners find antibodies for a range of therapeutic targets and applications.
About Caris Life Sciences
Caris Life Sciences is a precision medicine company that develops molecular profiling and artificial intelligence technologies to support cancer diagnosis and treatment decisions. Its services analyze the biological characteristics of a patient’s tumor to help physicians identify information that may guide care. The company’s offerings include tumor profiling based on DNA and RNA analysis, as well as blood-based testing. Caris also provides molecular data and research services to biopharmaceutical companies to support drug development and the study of cancer.
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
